Clinical trials in Novara – page 4

249 clinical trials in Novara, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in ItalyStudi-Clinici.it

Novara at a glance

249

clinical trials

Research sites1

Quick filters

249 trials in Novara

Open in trial search

Breast cancer+1

Recruiting

Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

Registered drugNo placebo

Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Acute myeloid leukaemia+3

Recruiting

Study comparing standard and reduced intensity treatment in patients with acute myeloid leukemia or chronic lymphocytic leukemia who have no detectable disease after initial therapy

Registered drugNo placebo

Study comparing standard and reduced intensity treatment in patients with acute myeloid leukemia or chronic lymphocytic leukemia who have no detectable disease after initial therapy

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Busulfan
Sponsor:Medizinische Hochschule Hannover

Contact Research Centre

Acute myocardial infarction

Recruiting

Study of ziltivekimab compared to placebo in patients with acute heart attack to evaluate its effects on coronary artery plaque reduction

Investigational

Study of ziltivekimab compared to placebo in patients with acute heart attack to evaluate its effects on coronary artery plaque reduction

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Ziltivekimab
Sponsor:ECRI-trials B.V.

Contact Research Centre

Non-small cell lung cancer+5

Recruiting

Study of cemiplimab treatment after surgery in patients with stage II-IIIA non-small cell lung cancer who have not received chemotherapy and have PD-L1 expression of 1% or higher

Registered drugNo placebo

Study of cemiplimab treatment after surgery in patients with stage II-IIIA non-small cell lung cancer who have not received chemotherapy and have PD-L1 expression of 1% or higher

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Cemiplimab
Sponsor:ETOP IBCSG Partners Foundation

Contact Research Centre

Autoimmune haemolytic anaemia

Recruiting

Study of rilzabrutinib tablets compared to placebo in adults with warm autoimmune hemolytic anemia

Investigational

Study of rilzabrutinib tablets compared to placebo in adults with warm autoimmune hemolytic anemia

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Rilzabrutinib
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Neovascular age-related macular degeneration+1

Recruiting

Study of Port Delivery System with ranibizumab given every 36 weeks in patients with neovascular age-related macular degeneration

Registered drugNo placebo

Study of Port Delivery System with ranibizumab given every 36 weeks in patients with neovascular age-related macular degeneration

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Ranibizumab
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Triple negative breast cancer

Recruiting

Evaluating sacituzumab tirumotecan alone or with pembrolizumab compared to standard treatment in untreated patients with metastatic triple-negative breast cancer with low PD-L1 expression

Registered drugNo placebo

Evaluating sacituzumab tirumotecan alone or with pembrolizumab compared to standard treatment in untreated patients with metastatic triple-negative breast cancer with low PD-L1 expression

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Polypoidal choroidal vasculopathy

Recruiting

Study on the Effects of Faricimab for Caucasian Patients with Polypoidal Choroidal Vasculopathy

Registered drugNo placebo

Study on the Effects of Faricimab for Caucasian Patients with Polypoidal Choroidal Vasculopathy

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Faricimab
Sponsor:Association For Innovation And Biomedical Research On Light And Image

Contact Research Centre

Chronic lymphocytic leukaemia+1

Recruiting

Study Comparing BGB-16673 to Drug Combinations for Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Treated with BTK and BCL2 Inhibitors

Registered drugNo placebo

Study Comparing BGB-16673 to Drug Combinations for Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Treated with BTK and BCL2 Inhibitors

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:BGB-16673
Sponsor:BeOne Medicines AG

Contact Research Centre

Chronic myelomonocytic leukaemia+1

Recruiting

Study Comparing Oral Azacitidine and Cedazuridine with Subcutaneous Azacitidine for Patients with Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

Registered drugNo placebo

Study Comparing Oral Azacitidine and Cedazuridine with Subcutaneous Azacitidine for Patients with Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Azacitidine
Sponsor:Taiho Oncology Inc.

Contact Research Centre

Thrombocytopenia

Recruiting

Study on the Effectiveness and Safety of Human Normal Immunoglobulin (IV) for Adults with Chronic Immune Thrombocytopenia

InvestigationalNo placebo

Study on the Effectiveness and Safety of Human Normal Immunoglobulin (IV) for Adults with Chronic Immune Thrombocytopenia

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Human Normal Immunoglobulin (Iv)
Sponsor:Kedrion S.p.A.

Contact Research Centre

Non-small cell lung cancer

Recruiting

Study on Cemiplimab and OSE2101 for Maintenance Therapy in Patients with ctDNA Positive Non-Small Cell Lung Cancer (NSCLC)

Registered drugNo placebo

Study on Cemiplimab and OSE2101 for Maintenance Therapy in Patients with ctDNA Positive Non-Small Cell Lung Cancer (NSCLC)

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Cemiplimab
Sponsor:Fondazione Ricerca Traslazionale

Contact Research Centre

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Novara

What the registry says about research in the country

01 Oncology Research

Clinical trials focusing on hematologic malignancies and solid tumors, investigating innovative treatments for various cancer types including leukemia, breast cancer, and lung cancer.

Advanced breast cancer therapies
Chronic myeloid leukemia treatments
Non-small cell lung cancer interventions

Studies evaluating combination therapies and targeted treatments to improve patient outcomes.

02 Cardiovascular Studies

Research focusing on heart failure prevention and treatment strategies, particularly exploring new drug combinations and their impact on cardiovascular outcomes.

Heart failure risk reduction
Cardiovascular death prevention
Chronic kidney disease management

Innovative approaches combining multiple therapeutic agents to address cardiovascular risks.

03 Autoimmune Conditions

Investigations into treatments for various autoimmune disorders, including Sjögren's Syndrome and rheumatoid arthritis, with emphasis on novel therapeutic approaches.

Biomarker-guided treatments
Long-term safety evaluations
Innovative therapeutic combinations

Focus on developing targeted therapies for better disease management and patient care.

Back to Italy All countries